|
|
 |
|
Viewing report
|
|
|
|
Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place
Bioseeker, June 2010, Pages: 913
This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market. Three out of four target strategies in Phase III and almost nine out of ten in Phase II are novel and innovative in their design. Small molecules and antibodies dominate as compound strategies, however the author foresees a competitive opening for peptide and protein based drugs to excel.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in breast cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any breast cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
Commercializing Pancreatic Cancer Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market
Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
|
|
|
|
